melanoma
In 2011 immunomodulation with ipilimumab, a monoclonal antibody targeting the ligand CTLA-4, has been approved for patients with advanced melanoma in first- and second-line treatment by the Food and Drug Administration (FDA) and in second-line treatment by the European Medicines Agency (EMA).
In 2011 immunomodulation with ipilimumab, a monoclonal antibody targeting the ligand <span class="gene" id="21802280-4-85-91">CTLA-4</span>, has been approved for patients with advanced <span class="disease" id="21802280-4-138-146">melanoma</span> in first- and second-line treatment by the Food and Drug Administration (FDA) and in second-line treatment by the European Medicines Agency (EMA).